Overview
Examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics
Improves the understanding of generation and engineering of human antibodies
Discusses strategies for development of novel therapies
Includes supplementary material: sn.pub/extras
Includes supplementary material: sn.pub/extras
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (19 chapters)
-
Front Matter
Keywords
About this book
Editors and Affiliations
About the editors
Mohammad Tabrizi, Ph.D., Vice President, Preclinical Development, AnaptysBio Inc. Mohammad Tabrizi is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. He is currently the Vice President of Preclinical Development at AnaptysBio, Inc., a privately held biotechnology company in San Diego CA, USA, the leader in Somatic HyperMutation (SHM) for development of therapeutic antibodies where he advances the preclinical development efforts.
Gadi Gazit Bornstein, Ph.D., Principal Scientist, AstraZeneca R&D Boston Dr. Bornstein has experience in research and development with an emphasis in development of therapeutic monoclonal antibodies in oncology. Dr. Bornstein is a Principal Scientist at AstraZeneca, where he currently leads several antibody programs within the Preclinical oncology portfolio. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the Keck School of Medicine of the University of Southern California. Dr. Bornstein completed his postdoctoral training at Stanford University School of Medicine in the Division of Immunology and Rheumatology. Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology Department. During his tenure at Abgenix, he was a project team leader and lead biologist for multiple antibody programs.
Scott L. Klakamp, Ph.D., Research Fellow, Biophysical Chemistry and Research Informatics, Takeda San Francisco Scott Klakamp is one of the leading scientists in utilizing Biacore®, KinExA®, and FACS techniques to measure the binding kinetics and equilibrium constants of human monoclonal antibody/antigen complexes. He has extensive experience in research and development involving the biophysical and analytical characterization of biologics and monoclonal antibodies (mAb). He has also contributed significantly to the clinical immunology field by applying highly rigorous analytical detection concepts, previously unknown to the discipline, to immunogenicity studies of therapeutic mAbs. Currently, he is a Research Fellow at Takeda San Francisco, the therapeutic monoclonal antibody discovery engine for Takeda Pharmaceutical Company, and leads the Biophysical Chemistry and Research Informatics Groups.
Bibliographic Information
Book Title: Development of Antibody-Based Therapeutics
Book Subtitle: Translational Considerations
Editors: Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp
DOI: https://doi.org/10.1007/978-1-4419-5955-3
Publisher: Springer New York, NY
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Science+Business Media, LLC, part of Springer Nature 2012
Softcover ISBN: 978-1-4899-9113-3Published: 08 May 2014
eBook ISBN: 978-1-4419-5955-3Published: 24 April 2012
Edition Number: 1
Number of Pages: XIV, 426
Topics: Pharmacy, Pharmacology/Toxicology, Biochemistry, general